We’re only a few weeks into the new year, and the Food and Drug Administration will soon make a decision that will affect pharmaceutical regulation for decades.
Last year, after failing an FDA-required futility test, Biogen abandoned its efforts to develop an Alzheimer’s treatment named aducanumab. However, after conducting an analysis using an expanded dataset, Biogen found the drug successfully curbed memory loss and helped maintain cognitive abilities
Biogen’s findings come at a critical time. About ten percent of the U.S. senior population suffers from Alzheimer’s. Medical researchers and drug developers have not been able to develop a new treatment for the
